TaiMed Biologics at IDWeek 2026

Oct 21–24, 2026 Washington, DC ~12k attendees Website

TaiMed Biologics brings 2 presentations to IDWeek 2026 in Washington. Its program centres on a stand-alone regimen of broadly neutralizing antibodies meant to keep HIV suppressed in people already on treatment. Single-dose escalation data report safety, drug levels and antiviral activity for one of these antibodies.

OrganizationIDWeek 2026 Attendance
TaiMed Biologics
Taipei, Taiwan
taimedbiologics.com
Biotech
Taiwanese biotech that developed ibalizumab (Trogarzo), an antibody for multidrug-resistant HIV, and is developing further HIV antibodies.
Poster
Thu Oct 22
12:15pm–1:30pm
TMB-365 and TMB-380: A potentially resistance repellant stand-alone maintenance bNAb regimen in suppressed people living with HIV-1 on combination antiretroviral therapy
Poster Hall B-C · Poster P-82
A3. Resistance mechanisms
Talk
Fri Oct 23
2:45pm–2:57pm
Part of Hot Off the Press: New Pathways in HIV Treatment
Single-dose escalation study of TMB-365 in people living with HIV: safety, pharmacokinetics, and antiviral activity
103 AB
HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship

Explore the full IDWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Washington. Leave your work email and we’ll be in touch.

Privacy

Download the full IDWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from TaiMed Biologics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction